Apollomics (APLM) Preferred Stock Liabilities (2022)
Apollomics (APLM) reported Preferred Stock Liabilities of $511.9 million for Q4 2022.
Apollomics (APLM) Preferred Stock Liabilities (2022) Analysis & Trends
Apollomics (APLM) has 1 years of Preferred Stock Liabilities data on file, last reported at $511.9 million in Q4 2022.
- Preferred Stock Liabilities for Q4 2022 came in at $511.9 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $511.9 million (changed N/A YoY), and the FY2022 annual result was $511.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $511.9 million in Q4 2022 per APLM's latest filing.
- Over five years, Preferred Stock Liabilities peaked at $511.9 million in Q4 2022 and troughed at $511.9 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Apollomics | 294.00 Mn | 294.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 511.86 Mn |